TVRD

Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Wall Street analysts forecast TVRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVRD is 16.00 USD with a low forecast of 4.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tvardi Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Tvardi Therapeutics Inc. EPS for the last quarter amounts to -0.59 USD, decreased -72.43 % YoY.

Tvardi Therapeutics Inc (TVRD) has 10 emplpoyees as of December 16 2025.

Today TVRD has the market capitalization of 39.59M USD.